Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Pancreatic Neoplasms 2Rectal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Head and Neck Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Esophageal Squamous Cell Carcinoma 1Esophageal 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Apatinib Combined 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 8apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × gimeracil × Clear all
NCT02527824 2017-08-23

Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer

Hallym University Medical Center

Phase 2 Unknown
31 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡